联邦制药国际控股有限公司（股份代码：03933）2025年财务数据显示，公司核心业务板块出现显著利润收缩。其中，中间体产品分部利润同比大幅减少约16亿元人民币；同期，原料药（大宗药品）业务利润亦下滑4亿元。
此番利润下滑凸显出公司在关键业务领域面临的经营压力。中间体产品作为医药制造的重要环节，其利润大幅收窄可能受到上游原材料成本上升及市场竞争加剧的双重影响。而原料药业务的利润收缩，则反映出全球医药市场格局变动及价格波动对该公司造成的冲击。
联邦制药国际控股有限公司（股份代码：03933）2025年财务数据显示，公司核心业务板块出现显著利润收缩。其中，中间体产品分部利润同比大幅减少约16亿元人民币；同期，原料药（大宗药品）业务利润亦下滑4亿元。
此番利润下滑凸显出公司在关键业务领域面临的经营压力。中间体产品作为医药制造的重要环节，其利润大幅收窄可能受到上游原材料成本上升及市场竞争加剧的双重影响。而原料药业务的利润收缩，则反映出全球医药市场格局变动及价格波动对该公司造成的冲击。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.